Tillhepo™ (Ursodeoxycholic acid (UDCA)) is commercialised by Tillotts from June 2020 on behalf of ABC Farmaceutici S.P.A.
UDCA is recommended as 1st line treatment for Primary Biliary Cholangitis (PBC) patients. It can dissolve gallstones <15mm in diameter and be prescribed for treating liver disease associated with cystic fibrosis for ages 6 to 18.
Tillhepo™ is available as 250mg and 500mg capsules and the trademark is registered in Germany and France.
Last update: June 2020
All trademarks used or mentioned here are protected by law. Tillotts Pharma AG’s trademarks include Tillotts™, Asacol™, Octasa™, Fivasa™, Lixacol™, Asacolon™, Colpermin™, VistaPrep™, Entocort™, Entocir™, Entocord™, Budecol™, Zentacort™ and Tillhepo™ are either registered or applied for in up to 70 countries (transfer of registrations to Tillotts pending in certain countries).
The rights to Asacol, including the rights to the trademark, are owned by Tillotts in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg. The rights to Entocort, including the rights to the trademark, are owned by Tillotts in various countries except for the USA.
Product information on this website is limited, with the aim of providing a summary for general information purposes for a wide audience regarding the activities of Tillotts, and could contain product details or information not accessible or valid in your country. Tillotts disclaims responsibility for access of information which may not comply with any regulation or standard in any particular country. More information may be available from local regulatory authorities, but not all products are available in each country. Please consult a healthcare professional for further information.